Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    Effects of Simvastatin on CSF Alzheimer’s Disease Biomarkers in Cognitively Normal Subjects
Previous Study | Return to List | Next Study

Effects of Simvastatin on Biomarkers (SimBio)

This study has been completed.
Seattle Institute for Biomedical and Clinical Research
VA Puget Sound Health Care System
Information provided by (Responsible Party):
Gail Li, University of Washington Identifier:
First received: June 9, 2010
Last updated: December 2, 2015
Last verified: December 2015

June 9, 2010
December 2, 2015
June 2010
October 2015   (Final data collection date for primary outcome measure)
Cerebral Spinal Fluid Biomarker measurements [ Time Frame: Baseline, Year 1 ]
Biomarkers of Alzheimer's Disease measured in cerebral spinal fluid: Aβ42, t-tau, p-tau181 and BDNF
Same as current
Complete list of historical versions of study NCT01142336 on Archive Site
Measures of inflammation or oxidative stress in cerebral spinal fluid. [ Time Frame: Baseline, Year 1 ]
Measures of inflammation or oxidative stress in cerebral spinal fluid: IL-6, IL-8, S100β, F2-isoprostanes, F4-neuroprostanes.
Same as current
Not Provided
Not Provided
Effects of Simvastatin on Biomarkers
Effects of Simvastatin on CSF AD Biomarkers in Cognitively Normal Subjects
A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.

The purpose of this study is to see if a drug called simvastatin (brand name Zocor) beneficially affects the level of certain molecules (such as proteins) in the spinal fluid of people. The molecules the investigators are measuring are thought to be important in the development of Alzheimer's disease (AD), and the investigators are testing whether simvastatin can change proteins to a level that is associated with a reduced risk for AD.

Simvastatin has been approved by the United States Food and Drug Administration (FDA) for the treatment of high cholesterol and to reduce the risk of coronary artery disease. It is an investigational drug in this study.

Participants will be randomly assigned to Placebo or Simvastatin. The investigators and the participant will be blinded. Randomization will be stratified by age and gender.

This study is being funded by the National Institute on Aging. The investigators expect about 120 people will take part in this study at the VA Puget Sound Health Care System over the course of a 2 year enrollment period.

This study will last up to 1 year. Participants will be asked to come to the VA in Seattle a total of 9 times, 2 of those times will be for lumbar punctures (also known as a spinal tap).

The investigators would also like to ask a person who knows the participant well (such as a spouse, child, sibling, or good friend) some questions about the participant's health, memory, mood and behavior, and abilities to do daily tasks at the beginning and the end of the study.

Participants must be cognitively normal, healthy, willing to have a lumbar puncture, and not need or take any medications to control cholesterol.

Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Alzheimer's Disease
  • Drug: Simvastatin
    Simvastatin 40mg qHS for 1 year
    Other Name: Zocor
  • Drug: Placebo
    Placebo 1 tablet qHS for 1 year
    Other Name: Sugar Pill
  • Experimental: Simvastatin
    Simvastatin 40mg qHS for 1 year
    Intervention: Drug: Simvastatin
  • Placebo Comparator: Placebo
    Placebo 1 tablet qHS for 1 year
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2015
October 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria (participants must meet the following criteria)

  • If female of childbearing potential, must have negative pregnancy test at baseline, and all subsequent visits.
  • Age 45 to 64 years inclusive.
  • Considered cognitively normal with no evidence of memory or other cognitive impairments (MMSE >26, Logical Memory delayed recall > 6, CDR score of 0).
  • Normal or only mildly elevated cholesterol which does not require drug therapy based on National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP-III) guidelines.
  • An LDL level above 70mg/dL.
  • Hamilton Depression Scale (HAM-D) score < 12.
  • BMI between 18 - 34 (or exception made by MD).
  • In good recent general health (i.e., no trauma or infection in the 4 weeks before LP).
  • On stable dose of non-exclusionary medications for the 4 weeks preceding the LP.
  • Platelet count >100,000.

Exclusion Criteria (participants must NOT satisfy any of the following conditions)

  • Any contraindications to LP, such as spinal deformity, severe disease or infection in the LP region, bleeding tendency, anticoagulant or blood-thinning medications.
  • Taken a statin medication in the past 12 months.
  • Any clinically significant laboratory abnormalities.
  • Any neurological disorders: multiple sclerosis, epilepsy, stroke, Parkinson's, other degenerative CNS disorders, or neuropathy with radicular involvement.
  • Acute or chronic major psychiatric disorders: schizophrenia, affective disorders, or severe anxiety disorders. (Dysthymia allowed, history of MDD allowed if currently in remission)
  • Unstable or poorly controlled medical problems such as: heart failure, diabetes (poorly controlled or insulin dependent), hypertension (BP >160/100), pulmonary disease with hypoxia or hypercapnia, significant liver disease or known hepatitis C seropositivity, renal failure, treatment for cancer in the past 2 years (other than non-melanoma skin cancer) or known HIV positive status.
  • Use of illegal drugs or alcohol abuse (>2 drinks/day or 10/week) within the past year.
  • Concurrent participation in another investigational drug study.
  • Use of any exclusionary medications in the 4 weeks prior to screening:

    • Drugs which could interact with statins: itraconazole, ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, nefazodone, amiodarone, cyclosporine, isoniazid, quinidine, or large quantities of grapefruit juice (>1 quart daily)
    • Central nervous system acting medications: antipsychotics, anti-Parkinson's disease medications, anti convulsants, or CNS stimulants
    • Chronic use of benzodiazepines, sedating antihistamines, or other sedative-hypnotic agents (prn use is allowed as long as it is not within 72 hours of LP or cognitive testing)
    • Medications affecting coagulation and/or inflammation: coumadin, potent anti-inflammatory medications (hydrocortisone, methotrexate or other potent immune-modulating medications), and anti-HIV medications (Aspirin up to 325 mg/day is allowed.)
    • Lipid-lowering drugs: fibrates or niacin >500mg/day (stable dose of omega-3 is allowed)
  • Does the subject's family history meet any of the following criteria?

    • Both parents had/have dementia
    • On one side of the family, over two consecutive generations three relatives had/have dementia?
    • One parent had an onset of dementia before age 60?
  • Does the subject have a major active autoimmune or immunological disorder?
Sexes Eligible for Study: All
45 Years to 64 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
00183 ( Other Identifier: VA Puget Sound Health System MIRB# )
Not Provided
Not Provided
Not Provided
Gail Li, University of Washington
University of Washington
  • Seattle Institute for Biomedical and Clinical Research
  • VA Puget Sound Health Care System
Principal Investigator: Gail Li, MD, PhD University of Washington
University of Washington
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP